Fakhri HR, Janket SJ, Jackson EA, Baird AE, Dinnocenzo R, Meurman JH. Tutorial in oral antithrombotic therapy: Biology and dental
implications. Med Oral Patol Oral Cir Bucal. 2013 May 1;18 (3):e461-72.
doi:10.4317/medoral.19140
http://dx.doi.org/doi:10.4317/medoral.19140
|
1. Institute of Medicine (US) Committee on Preventing the Global
Epidemic of Cardiovascular Disease: Meeting the Challenges in Developing
Countries; Fuster V, Kelly BB, editors. Promoting
Cardiovascular Health in the Developing World: A Critical Challenge to
Achieve Global Health. Washington (DC):
National Academies Press (US); 2010. |
|
|||
|
||||
|
|
||||
|
2. Kosyfaki P, Att
W, Strub JR. The dental patient on oral
anticoagulant medication: a literature review. J Oral Rehabil. 2011;38:615-33. |
||||
|
|
||||
|
3. Lip
GY, Tse HF, Lane DA.
Atrial fibrillation. Lancet.
2012;379:648-61. |
||||
|
|
||||
|
4. Aframian
DJ, Lalla RV, Peterson DE. Management of dental
patients taking common hemostasis-altering
medications. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103 Suppl45:e1-11. |
||||
|
|
||||
|
5. Devani P, Lavery
KM, Howell CJ. Dental extractions in patients on warfarin:
is alteration of anticoagulant regime necessary? Br J Oral Maxillofac Surg. 1998;36:107-11. |
||||
|
|
||||
|
6. Madrid C, Sanz M. What influence do
anticoagulants have on oral implant therapy? A systematic review. Clin Oral Implants Res. 2009;20
Suppl4:96-106. |
||||
|
|
||||
|
7. Nematullah A, Alabousi
A, Blanas N, Douketis JD,
Sutherland SE. Dental surgery for patients on anticoagulant therapy with warfarin: a systematic review and meta-analysis. J Can Dent Assoc. 2009;75:41. |
||||
|
|
||||
|
8. Firriolo FJ, Hupp
WS. Beyond warfarin: the new generation of oral
anticoagulants and their implications for the management of dental patients.
Oral Surg Oral Med Oral Pathol
Oral Radiol Endod. 2012;113:431-41. |
||||
|
|
||||
|
9. Little JW. New oral anticoagulants: Will they replace warfarin?. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:575-80. |
||||
|
|
||||
|
10. Davie EW, Kirby EP. Molecular mechanisms in blood coagulation. Curr Top Cell Regul. 1973;7:51-86. |
||||
|
|
||||
|
11. Macfarlane RG. A clotting scheme for 1964. Thromb
Diath Haemorrh Suppl.
1965;17:45-52. |
||||
|
|
||||
|
12. Hoffman M, Monroe DM. A cell-based model of hemostasis.
Thromb Haemost. 2001;85:958-65. |
||||
|
|
||||
|
13. Adams RL, Bird RJ. Review article: Coagulation cascade and
therapeutics update: relevance to nephrology. Part 1: Overview of
coagulation, thrombophilias and history of
anticoagulants. Nephrology (Carlton). 2009;14:462-70. |
||||
|
|
||||
|
14. Osterud B, Rapaport
SI. Activation of factor IX by the reaction product of tissue factor and
factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad
Sci U S A. 1977;74:5260-4. |
||||
|
|
||||
|
15. Howard EL, Becker KC, Rusconi CP, Becker
RC. Factor IXa inhibitors as novel anticoagulants. Arterioscler Thromb Vasc Biol. 2007;27:722-7. |
||||
|
|
||||
|
16. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl
J Med. 2012;366:864-6. |
||||
|
|
||||
|
17. Schecter AD, Rollins BJ, Zhang YJ, Charo IF, Fallon JT, Rossikhina
M, et al. Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle
and THP-1 cells. J Biol
Chem. 1997;272:28568-73. |
||||
|
|
||||
|
18. Conway EM, Bach R, Rosenberg RD, Konigsberg WH. Tumor necrosis
factor enhances expression of tissue factor mRNA in endothelial cells. Thromb Res. 1989 ;53:231-41. |
||||
|
|
||||
|
19. Siller-Matula JM, Krumphuber
J, Jilma B. Pharmacokinetic, pharmacodynamic
and clinical profile of novel antiplatelet drugs
targeting vascular diseases. Br J Pharmacol. 2010;159:502-17. |
||||
|
|
||||
|
20. Mills DC, Puri R, Hu
CJ, Minniti C, Grana G,
Freedman MD, et al. Clopidogrel inhibits the
binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb. 1992;12:430-6. |
||||
|
|
||||
|
21. Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK,
Cornel JH, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in
the PLATelet inhibition and patient Outcomes
(PLATO) trial. Eur Heart J. 2011;32:2933-44. |
||||
|
|
||||
|
22. McNicol A, Israels
SJ. Platelets and anti-platelet therapy. J Pharmacol
Sci. 2003;93:381-96. |
||||
|
|
||||
|
23. Deedwania PC, Huang GW. Role of emerging
antithrombotic therapy in the prevention of cardioembolic
complications in patients with atrial fibrillation.
Am J Cardiovasc
Drugs. 2011;11:265-75. |
||||
|
|
||||
|
24. Hankey GJ, Patel MR, Stevens SR, Becker
RC, Breithardt G, Carolei
A, et al. Rivaroxaban compared with warfarin in patients with atrial
fibrillation and previous stroke or transient ischaemic
attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012;11:315-22. |
||||
|
|
||||
|
25. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh
A, et al. Dabigatran versus warfarin
in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. |
||||
|
|
||||
|
26. Hankey GJ, Eikelboom
JW. Dabigatran etexilate:
a new oral thrombin inhibitor. Circulation. 2011;123:1436-50. |
||||
|
|
||||
|
27. Watanabe
M, Qureshi AI, Siddiqui
FM. Periprocedural management of patients on dabigatran etexilate treatment.
AJNR Am J Neuroradiol. 2011;32:E166. |
||||
|
|
||||
|
28. Douketis JD, Spyropoulos
AC, Spencer FA, Mayr M, Jaffer
AK, Eckman MH, et al. Perioperative
management of antithrombotic therapy: Antithrombotic Therapy and Prevention
of Thrombosis, 9th ed: American College of Chest
Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141
Suppl2:e326S-50S. |
||||
|
|
||||
|
29. Kassab MM, Radmer
TW, Glore JW, Visotcky A,
Robertson J, Degroot B. A retrospective review of
clinical international normalized ratio results and their implications. J Am Dent Assoc. 2011;142:1252-7. |
||||
|
|
||||
|
30. Scully C, Wolff A. Oral surgery in patients on anticoagulant
therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;94:57-64. |
||||
|
|
||||
|
31. Bacci
C, Maglione M, Favero L, Perini A, Di Lenarda R, Berengo
M, et al. Management of dental extraction in patients undergoing anticoagulant treatment.
Results from a large, multicentre, prospective, case-control study. Thromb Haemost. 2010;104:972-5. |
||||
|
|
||||
|
32. Eichhorn W, Burkert
J, Vorwig O, Blessmann M,
Cachovan G, Zeuch J, Eichhorn M, Heiland M. Bleeding
incidence after oral surgery with continued oral anticoagulation. Clin Oral Investig. 2012;16:1371-6. |
||||
|
|
||||
|
33. Brooks AS. Delayed complications of tooth extraction in patients
taking warfarin, antibiotics, and other
medications. J Oral Maxillofac
Surg. 2011;69:977-9. |
||||
|
|
||||
|
34. Lockhart PB, Gibson J, Pond SH, Leitch
J. Dental management considerations for the patient with an acquired coagulopathy. Part 2:
Coagulopathies from drugs. Br Dent J. 2003;195:495-501. |
||||
|
|
||||
|
35. Muthukrishnan A, Bishop K. An assessment
of the management of patients on warfarin by
general dental practitioners in South West Wales. Br Dent J. 2003;195:567-70. |
||||
|
|
||||
|
36. Ball JH. Management of the anticoagulated
dental patient. Compend Contin
Educ Dent. 1996;17:1100-2. |
||||
|
|
||||
|
37. Ortel TL. Perioperative
management of patients on chronic antithrombotic therapy. Blood. 2012;120:4699-705. |
||||
|
|
||||
|
38. Kaatz S, Kouides
PA, Garcia DA, Spyropolous AC, Crowther
M, Douketis JD, et al. Guidance on the emergent
reversal of oral thrombin and factor Xa inhibitors.
Am J Hematol. 2012;87
Suppl1:S141-5. |
||||
|
|
||||
|
39. Eerenberg ES, Kamphuisen
PW, Sijpkens MK, Meijers
JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized,
placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573-9. |
||||
|
|
||||
|
40. Marlu R, Hodaj
E, Paris A, Albaladejo P, Crackowski
JL, Pernod G. Effect of non-specific reversal
agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised
crossover ex vivo study in healthy volunteers. Thromb
Haemost. 2012;108:217-24. |
||||
|
|
||||
|
41. Morimoto Y, Niwa H, Nakatani
T. On the use of prothrombin complex concentrate in
patients with coagulopathy requiring tooth
extraction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110:e7-10. |
||||
|
|
||||
|
42. Akopov SE, Suzuki S, Fredieu
A, Kidwell CS, Saver JL, Cohen SN. Withdrawal of warfarin
prior to a surgical procedure: time to follow the guidelines?. Cerebrovasc Dis. 2005;19:337-42. |
||||
|
|
||||
|
43. Garcia DA, Regan S, Henault LE, Upadhyay A, Baker J, Othman M, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med. 2008;168:63-9. |
||||
|
|
||||